|
Adult Classical Hodgkin Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In classical Hodgkin lymphoma (HL), the malignant Reed-Sternberg cells express the cell surface marker CD30.
|
31811017 |
2020 |
|
Adult Classical Hodgkin Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
High CD30-expression by B- and T-cells was associated with a decreased risk of cHL [(OR = 0.10, 95 % CI:0.03-0.39) and (OR = 0.13, 95 % CI:0.01-0.71), respectively], which remained significant for CD30 + B-cells (OR = 0.15, 95 % CI:0.03-0.60) in multivariate analyses.
|
31787352 |
2020 |
|
Adult Classical Hodgkin Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this retrospective analysis, we aimed to assess this therapy's efficacy in unselected patients with cHL and CD30+ peripheral T cell lymphoma (PTCL).
|
31838747 |
2020 |
|
Adult Classical Hodgkin Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The efficacy of the CD30-directed antibody-drug conjugate (ADC) brentuximab vedotin was established in combination with chemotherapy as frontline treatment for advanced classical Hodgkin's lymphoma in the randomized phase III ECHELON-1 study.
|
31152605 |
2019 |
|
Adult Classical Hodgkin Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this investigation was to evaluate the benefits and drawbacks of three-dimensional imaging of CD30+ cells in classical Hodgkin Lymphoma (cHL) in comparison to CD30+ lymphoid cells in reactive lymphoid tissues.
|
31648255 |
2019 |
|
Adult Classical Hodgkin Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Anaplastic large cell lymphoma (ALCL) and classical Hodgkin lymphoma (cHL) are lymphomas that contain CD30-expressing tumor cells and have numerous pathological similarities.
|
31581676 |
2019 |
|
Adult Classical Hodgkin Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The two lesions initially diagnosed as cHL showed scattered HRS-like cells with CD30+, CD15+, PAX5+, CD20-, Epstein Barr Virus (EBV) + classical phenotype.
|
30370547 |
2019 |
|
Adult Classical Hodgkin Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
One hundred and one lymph node samples featuring cHL histology were analyzed for both CD30 and CAIX by immunohistochemistry.
|
31311071 |
2019 |
|
Adult Classical Hodgkin Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These observations thus provide new insights into our understanding of the biological roles of CD30 in normal and malignant cells and, in particular, in cHL.
|
29431186 |
2018 |
|
Adult Classical Hodgkin Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The CD30 antibody-drug conjugate (ADC) brentuximab vedotin and the PD-1 antibodies nivolumab and pembrolizumab are highly efficacious in treating relapsed and/or refractory cHL.
|
29685160 |
2018 |
|
Adult Classical Hodgkin Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Monoclonal antibody technology allowed for the successful development of CD30-specific immunotoxins, bispecific antibodies, and reprogrammed autologous T cells with the first one already approved for the treatment of high risk or relapsed cHL.
|
29915720 |
2018 |
|
Adult Classical Hodgkin Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Classical Hodgkin Lymphoma (cHL) is primarily a B cell lymphoid neoplasm and a member of the CD30-positive lymphomas. cHL and the other CD30-positive lymphomas are characterized by the elevated expression and/or constitutive activation of the activator protein-1 (AP-1) family transcription factors, c-Jun and JunB; however, the specific roles they play in the pathobiology of cHL are unclear.
|
30375407 |
2018 |
|
Adult Classical Hodgkin Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD30-targeted oncolytic viruses as novel therapeutic approach against classical Hodgkin lymphoma.
|
29560124 |
2018 |
|
Adult Classical Hodgkin Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The CD30 antigen is strongly expressed on neoplastic cells in classical Hodgkin lymphoma (HL), anaplastic large cell lymphoma (ALCL) and other hematologic malignancies (such as DLBCL and cutaneous TCL), while is almost undetectable on healthy tissues, representing an ideal immunotherapeutic target.
|
27592544 |
2017 |
|
Adult Classical Hodgkin Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In noncomparative, phase 2 trials and in the real-world setting, salvage therapy with brentuximab vedotin resulted in high objective response (complete plus partial remission) rates in patients with relapsed or refractory CD30-positive HL, including as retreatment in patients who had an objective response to previous brentuximab vedotin therapy and subsequently relapsed.
|
28190142 |
2017 |
|
Adult Classical Hodgkin Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This review describes the role of CD30 and the use of CD30-targeted agents in HL, ALCL, and other lymphomas, including review of relevant trials of BV.
|
27927047 |
2017 |
|
Adult Classical Hodgkin Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In HL cell lines BFA did not affect CD30 expression or constitutive nuclear factor (NF)-κB activity, both of which are critical for HL cell survival.
|
26105086 |
2015 |
|
Adult Classical Hodgkin Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Two cases were "monomorphic" with immunoblastic histology, and 5 cases were "polymorphic" with histologic aspects reminiscent of nodular lymphocyte-predominant Hodgkin lymphoma (2 cases) and of CD30+ classical Hodgkin lymphoma (3 cases).
|
25704629 |
2015 |
|
Adult Classical Hodgkin Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
CD30, originally identified as a cell-surface marker of Reed-Sternberg and Hodgkin cells of classical Hodgkin lymphoma, is also expressed by several types of non-Hodgkin lymphoma, including a subset of diffuse large B-cell lymphoma (DLBCL).
|
23343832 |
2013 |
|
Adult Classical Hodgkin Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
As upregulation of CD99 led to a decrease in cHL diagnosis marker CD30 and CD15 and an increase in plasma-cell differentiation marker CD38 and the restoration of B-cell makers PAX5, CD79α and CD19, we suggest that downregulated CD99 leads to the prevention of plasma-cell differentiation in Hodgkin/Reed-Sternberg (H/RS) cells.
|
22020966 |
2012 |
|
Adult Classical Hodgkin Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Five cases originally diagnosed as cHL were revised as CD30-positive TCL.
|
22367293 |
2012 |
|
Adult Classical Hodgkin Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Archived tissues from 27 CD30(+) HL plus control samples were analyzed by DNA microarrays.
|
21385932 |
2011 |
|
Adult Classical Hodgkin Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
All ptHL expressed CD15, CD30 and LMP-1 of EBV; the B-cell markers BOB-1, Oct2, CD79a and CD20 were more commonly expressed in ptHL versus cHL (100%, 86%, 50% and 38% in ptHL compared to 6%, 14%, 10% and 33% in cHL, respectively); all ptHL expressed phosphoinositide 3-kinase (PI3K) versus 81% of cHL; 2/6 (33%) ptHL displayed gains at 9p24 that were similar to cHL (32%).
|
19705967 |
2009 |
|
Adult Classical Hodgkin Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Immunohistochemical studies revealed that the large atypical cells were CD30 (+), CD15 (weakly +), CD20 (-), CD45 (-), Pax5 (weakly +), BOB.1 (-), and Oct2 (-), indicating the coexistence of SMZL with cHL.
|
18486899 |
2008 |
|
Adult Classical Hodgkin Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We aim to study the expression pattern of CD30, CD40 and CD95 in classical Hodgkin's lymphoma (cHL) and to correlate the expressions with proliferation and apoptosis in the Hodgkin/Reed-Sternberg (H/RS) cells of cHL with or without associated Epstein-Barr virus (EBV) infection.
|
14555388 |
2003 |